Dr. Siegel's point was that "smoking" is not a disease. So a claim of "smoking cessation" is not a claim that one's product is being used to treat a disease.
All products that the FDA refers to as "smoking cessation" products were actually approved for the purpose of "nicotine cessation." The nicotine replacement therapy (NRT) products came with directions to first switch 100% to the product (whether patch, gum, lozenge, nasal spray, or inhaler) and then gradually reduce the amount of that product over time. In the case of the patch, the directions were to use the highest dose (21 mg in the U.S.) for 6 weeks, then switch to the next dose (14 mg in the U.S.) for 3 weeks, and then to the lowest dose (7 mg in the U.S.) for an additional 3 weeks. After this 12-week regimen, you were considered cured.
Patients were warned that smoking a cigarette while using the NRT product could cause a heart attack. This created the bizarre situation of people ripping off their nicotine patch between planes, smoking a cigarette, and then slapping the patch back on.
The only problem with the "cure" is that shortly after "treatment" stopped, relapse would begin. Even to this day, between 90% and 97% of those using the approved NRT products have relapsed to smoking at the end of one year.
Dr. Siegel urged vendors to read Judge Leon's opinion document on the Soterra decision (available here:
http://www.casaa.org/uploads/SE-vs-FDA-Opinion.pdf)
Judge Leon opined that what makes a product a drug that can be regulated under the Food, Drug and Cosmetics Act (FDCA) is "intended use." He pointed out that the FDCA defines a drug or drug-device combination as an article "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease." 21 U.S.C. §
But Judge Leon did not allege that "smoking cessation" is not a therapeutic claim. In a footnote, he stated:
15 To the extent that smoking cessation is a therapeutic claim distinct from the treatment of nicotine addiction and withdrawal, the Court is aware that the two customer testimonials referenced above suggest that electronic cigarettes are intended for smoking cessation, if not for treating nicotine dependence (as suggested by FDA). Given Smoking Everywhere's express disclaimer that its electronic cigarettes are not intended as a smoking cessation device, (AR DET 1), and given the overwhelming evidence in the record that its electronic cigarettes are intended merely as a recreational alternative to traditional cigarettes (and not necessarily as a therapeutic replacement for traditional cigarettes), the Court concludes that the two testimonials cited by FDA are not alone sufficient to support a finding that the product appears to be intended to help customers quit smoking.
So the judge indicated that customer testimonials are not necessarily health claims. However, even after the Soterra case finally came to a close, the FDA was still sending warning letters to vendors regarding testimonials posted on their web site. So it does no good to be technically correct if there are agencies intent on having their own way.
You can fight city hall, but the fight could prove to be an expensive one.
I believe that Janusxvii's suggestion is a wise one. Advertising aimed at urging smokers to switch away from conventional cigarettes to e-cigarettes cannot be construed (even by as stubborn an entity as the FDA) as a health claim as long as no mention is made of improved health as a result of that switch.